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Abstract Thirty patients with Schamberg's disease were started on pentoxifylline (400 mg three times 
daily) for a period of 9 weeks. Improvement was assessed at 3 weekly intervals by two 
observers independently and graded as mild (<25%), moderate (25-50%) and marked 
(>50%). Marked improvement was observed in 15/30 (50%) patients. We conclude that 
pentoxifylline should be considered as first line therapy in all patients with Schamberg's 
disease. 
Keywords 
Schamberg’s disease, pentoxifylline 
Introduction
Schamberg's disease (progressive pigmented 
purpuric dermatoses) is a capillaritis of 
unknown etiology characterized by orange 
to fawn-colored macules and plaques 
usually localized to the lower limbs.1 
Characteristic 'cayenne pepper' spots due to 
hemosiderin deposition in the skin are seen 
at the periphery of the lesions.1 
Histopathology consists of a superficial 
lymphocytic perivascular inflammation with 
increased capillaries and siderophages in the 
upper dermis.2 The disease follows a chronic 
course with spontaneous clearance in a few 
cases. Treatment modalities which have 
been used include topical and systemic 
corticosteroids, vitamin C and topical and 
systemic anti-inflammatory agents. 
Pentoxifylline, a methylxanthine derivatice, 
has been used successfully in treatment of 
various types of vasculitides, specially 
leucocytoclastic vasculitis. A report of its 
successful use in Schamberg's disease' 
prompted us to conduct a larger trial. 
Pentoxifylline is well absorbed orally but 
undergoes extensive first-pass metabolism in 
the liver before being excreted in the urine. 
Peak plasma levels occur within 2 hours, 
and the half-life is 4 to 6 hours. 
Patients and methods 
Thirty patients presenting with characteristic 
lesions of Schamberg's disease confirmed on 
histopathology were included in the trial. 
Pentoxifylline was started in a dose of 400 
mg three times daily. No other topical or 
systemic treatment was given during the 
study period. Response to treatment was 
assessed independently by two observers at 
3 week intervals and graded as percentage of 
clearance of lesions. Improvement was 
graded as mild (<25%), moderate (25-50%) 
and marked (>50%). 
Results
The improvement as assessed by two 
different observers at  3  weekly  intervals  is 
